- Results from the Phase 2 clinical study of ONIVYDE in previously untreated front-line metastatic pancreatic cancer in the first half of 2017;
Catalyst
Slingshot members are tracking this event:
Phase 3 data of ONIVYDE for first line pancreatic due 1H 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 11, 2016
Occurred Source:
http://investors.merrimackpharma.com/news-releases/news-release-details/final-results-napoli-1-study-confirm-overall-survival-and
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2 Data, Onivyde, First Line Pancreatic
